Specifically, the breast cancer line BT-474 (EC50 56.4±13.8 μM, Fig. 2A) expresses high levels of ErbB3 and ErbB2 and exhibits ligand-independent ErbB3 activation [25], [28]. Here, ERBB2 is linked to breast carcinoma.